Chemotherapy plus bevacizumab with or without anti-programmed death 1 immunotherapy as the second-line therapy in colorectal cancer

Figure 7 Lactate dehydrogenase as a predictive biomarker of progression-free survival. A: Receiver operating characteristic curves of lactate dehydrogenase (LDH) at 9 months, 12 months, and 15 months before patients receiving chemotherapy combined with bevacizumab and anti-programmed death 1 immunotherapy; B: Survival curves of LDH before patients receiving chemotherapy combined with bevacizumab and anti-programmed death 1 immunotherapy (high group: LDH ≥ 240 mmol/L and low group LDH < 240 mmol/L). ACU: Area under curve.